Search all trials

Find therapies in clinical trials near you – page 26

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Colitis ulcerative

Not recruiting

Investigational

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational

France

Participants:18–64 years
Substances:Golimumab

Contact Research Centre

Thrombotic microangiopathy

Not recruiting

Registered drugNo placebo

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years

Contact Research Centre

Colitis ulcerative

Not recruiting

Registered drugNo placebo

Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adalimumab

Contact Research Centre

Psoriasis

Not recruiting

Registered drug

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Brodalumab

Contact Research Centre

Myelodysplastic syndrome

Not recruiting

Registered drug

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Adenocarcinoma gastric

Not recruiting

Registered drugNo placebo

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Paclitaxel

Contact Research Centre

Colitis ulcerative

Not recruiting

InvestigationalNo placebo

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obefazimod

Contact Research Centre

Pulmonary hypertension

Not recruiting

Investigational

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational

France

Participants:18–64 years · 65+ years
Substances:Ralinepag

Contact Research Centre

Pulmonary embolism

Not recruiting

Registered drug

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Alteplase

Contact Research Centre

Neoplasm malignant+1

Not recruiting

Registered drugNo placebo

Screening for Hidden Cancer Using FDG PET/CT and Gallium (68Ga) Chloride in Patients Aged 50+ with Unexplained Blood Clots

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gallium (68Ga) Chloride

Contact Research Centre

Crohn's disease

Not recruiting

Investigational

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Risankizumab

Contact Research Centre

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Not recruiting

Registered drugNo placebo

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Binimetinib

Contact Research Centre

Find therapies in clinical trials near you – page 26

349 trials match your criteria

Colitis ulcerative

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Thrombotic microangiopathy

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Colitis ulcerative

Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab

Psoriasis

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Myelodysplastic syndrome

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Adenocarcinoma gastric

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Colitis ulcerative

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Pulmonary hypertension

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Pulmonary embolism

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Neoplasm malignant+1

Screening for Hidden Cancer Using FDG PET/CT and Gallium (68Ga) Chloride in Patients Aged 50+ with Unexplained Blood Clots

Crohn's disease

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.